Loading...
•
Dec 31, 2019
Mersana Q4 2019 Earnings Report
Mersana announced its Q4 2019 financial results and provided a business update.
Key Takeaways
Mersana Therapeutics reported its Q4 and full year 2019 financial results, highlighting the upcoming presentation of XMT-1536 data at the SGO 2020 Annual Meeting and planned data disclosures throughout the year. The company's cash, cash equivalents, and marketable securities were $99.8 million as of December 31, 2019.
XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at SGO 2020 Annual Meeting on Women’s Cancer.
XMT-1536 interim Phase 1 dose expansion data to be presented in 2Q 2020 with more mature data expected in 2H 2020.
The company will present preclinical data on ADCs created with the Dolasynthen and Immunosynthen platforms at the AACR Annual Meeting.
Cash, cash equivalents and marketable securities as of December 31, 2019, were $99.8 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...